Two parents, Ricardo García and Cesare Spadoni, an entrepreneur and a scientist united by childhood cancer, lead Oncoheroes Biosciences, the first company dedicated to developing new drugs for pediatric oncology.
Childhood cancer is the leading cause of death by disease in children aged 1 to 19. Unfortunately, there are only seven drugs designed and initially approved for pediatric cancer compared to over 200 in adults.
Despite 400,000 children being diagnosed and 90,000 lost each year, childhood cancer is considered an orphan disease. Regrettably, the pharmaceutical industry and venture capitalists show limited interest in backing essential initiatives beyond academic research, given the comparatively small market size of pediatric cancer in contrast to adults.
Without leadership from the industry, it is almost impossible to approve new drugs.
UNPRECEDENTED OPPORTUNITY
Oncoheroes’ lead compound, volasertib, is ready to be evaluated in an international clinical trial with the hope of finding signs of efficacy in several types of pediatric cancers (Ewing sarcoma, medulloblastoma, neuroblastoma, rhabdomyosarcoma, diffuse midline glioma (DMG), including diffuse intrinsic pontine glioma (DIPG)).
Oncoheroes is partnering with Hopp Children's Cancer Center Heidelberg (KiTZ), the leading academic institution of this study, and will provide the drug and industry support. Volasertib will be evaluated in combination with vinorelbine in approximately 20 sites across the EU, UK and Australia, targeting +100 patients who have exhausted available treatments.
This clinical trial would be the first comprehensive pediatric evaluation of this promising compound and would serve as the basis for a later global registration trial in the most suitable pediatric indication.
WE NEED YOU
The trial is largely supported by the German Foundation, Ein Herz für Kinder. However, funding is still the only obstacle preventing the launch of the trial. Oncoheroes is raising ONE MILLION EUROS. Help us achieve it.
In 2021, Fundacion Olivares joined forces with Oncoheroes by funding the advancement of Volasertib. Once again, they demonstrate their commitment through a donation campaign that will be used to finance Volasertib’s trial.
Capital Cellis an online investment platform allowing individuals or organizations to partner with socially impactful companies in the life sciences sector.
Oncoheroes, valued at over 21 million euros, has issued more than 15 million shares at the unit price of 1.67€ per share. Interested parties can acquire shares through Capital Cell with a minimum purchase limit of only 1,000 euros.
Invest in Oncoheroes' investment round to finance Volasertib’s trial and become a partner in saving the lives of children with cancer.
